title: Angiotensin peptides and lung cancer.
abstract: Lung cancer is a leading cause of death in both men and women, with over 1,000,000 new cases diagnosed worldwide annually and a 5-year survival rate of only 14%, a figure that has improved little in the past thirty years. This poor prognosis suggests a need for novel approaches for the treatment and prevention of lung cancer. The renin-angiotensin system is an established, primary regulator of blood pressure, homeostasis, and natriuresis; however, compelling evidence indicates that the angiotensin peptides also play a role in cell proliferation and inflammation. Angiotensin II is a vasoconstrictor, a mitogen, and an angiogenic factor, while angiotensin-(1-7) has vasodilator, anti-proliferative, and anti-angiogenic properties. This review focuses on studies examining the renin-angiotensin system in pulmonary cancers and whether clinical intervention of this pathway may serve as an effective chemotherapeutic and/or chemopreventive modality for lung cancer.
authors.affiliation: Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. pgallagh@wfubmc.edu
authors.forename: Patricia E
authors.initials: PE
authors.lastname: Gallagher
authors.forename: Katherine
authors.initials: K
authors.lastname: Cook
authors.forename: David
authors.initials: D
authors.lastname: Soto-Pantoja
authors.forename: Jyotsana
authors.initials: J
authors.lastname: Menon
authors.forename: E Ann
authors.initials: EA
authors.lastname: Tallant
mesh_terms: D000809:Angiotensins / Q000378:metabolism* / Q000494:pharmacology*; D000818:Animals; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism / Q000494:pharmacology; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology*
chemical_list: D000809:Angiotensins; D010446:Peptide Fragments